NCT04922307Active, not recruiting
Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer
Source: ClinicalTrials.gov · Last updated 12 Nov 2025
Brief summary (registry, in English)
The Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer Trial (RESTRICT). The primary objective is to reduce the number of units of allogenic blood transfusion in locally advanced kidney cancer (≥ cT2). Secondary objectives include reduction in perioperative complications, assessment of recurrence free-survival and improving overall survival.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 240 (estimated)
- First submitted
- 4 Jun 2021
- Start date
- 23 Jul 2021
- Primary completion date
- 12 Feb 2025
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- Kidney cancer
- NCT number
- NCT04922307
What you commit to
- Study type: Interventional
- Planned participants: 240
- From 23 Jul 2021 to the primary completion date, 12 Feb 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Non-surgical candidate
Other illness
- Unstable angina.
Age
- Male and female younger than 18 years old.
Who the study is looking for
- Renal masses ≥ cT2 (by any conventional imaging).
- N1 or M1 disease is allowed if they are deemed surgical candidates (including cytoreductive nephrectomy).
- Male and female patients.
- 18 and older.
- Ejection fraction (EF) ≥ 45% by echocardiogram (ECHO).
- Adequate organ function as defined by:
- Hemoglobin ≥ 9 g/dL. Pre-operative allogenic blood transfusion is allowed.
- Platelets ≥ 100.000/μl.
- Albumin ≥ 2.5 g/dL.
- Aspartate Aminotransferase (AST) and alanine transaminase (ALT) ≤ 75U/L or total bilirubin ≤ 2.0 mg/dL.
- WBC within institutional normal limits.
- PT within institutional normal limits.
- INR \< 1.5 and PTT normal.
- Consent and compliance with all aspects of the study protocol.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Winship Cancer Institute at Emory University Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Unknown status |
| H Lee Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.